In conclusion, identification of the adaptability network with S100β has the potential to provide new information regarding the response of the patient tumor to ongoing endocrine therapy and act as a companion diagnostic to increase the efficacy of combined tyrosine kinase inhibitor treatment. The gene discussed is S100B; the disease is neoplasm.